Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Shares Outstanding (Weighted Average) (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 28306.38% to $4.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Sep 2025, up 28306.38% year-over-year, with the annual reading at $767.0 for FY2024, 89.79% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $4.0 million in Q3 2025 for Aptevo Therapeutics, down from $12.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $12.6 million in Q2 2025 to a low of $767.0 in Q4 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $3.0 million across 5 years, with a median of $4.0 million in 2025.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 99.85% in 2023 and later soared 441170.44% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $4.7 million in 2021, then rose by 8.8% to $5.1 million in 2022, then crashed by 99.85% to $7515.0 in 2023, then tumbled by 89.79% to $767.0 in 2024, then skyrocketed by 527806.91% to $4.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for APVO at $4.0 million in Q3 2025, $12.6 million in Q2 2025, and $1.5 million in Q1 2025.